Atul Sharma

Atul Sharma

Auto-generated profile, based on publicly available information

Atul Sharma

Department of Medical Oncology, All India Institute of Medical Sciences , New Delhi

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASAtul Sharma
Atul Sharma
ADAmit Dutt Dwary
Amit Dutt Dwary
BMBidhu Kalyan Mohanti
Bidhu Kalyan Mohanti
SDSurya V. Deo
Surya V. Deo
SPSujoy Pal
Sujoy Pal
SCSurendra Pal Chaudhary
Surendra Pal Chaudhary
Purpose: We designed this study to evaluate efficacy of modified gemcitabine and oxaliplatin (mGEMOX) over best supportive care (BSC) or fluorouracil (FU) and folinic acid (FA) in unresectable gall bladder cancer (GBC). Patients and Methods: Patients with unresectable GBC were enrolled for single center randomized study. Arm A, BSC; arm B, FU 425 mg/m2 and FA 20 mg/m2 intravenous (IV) bolus weekly for 30 weeks (FUFA); arm C, gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles. Eighty-one patients were randomly assigned, arms A (n = 27), B (n = 28), and C (n = 26). Results: Complete response plus partial response in the three groups was 0 (0%), four (14.3%), and eight (30.8%) respectively (P < .001). Two patients in the mGEMOX arm and one patient in the FUFA arm underwent curative resection after chemotherapy. One patient in the mGEMOX arm had complete pathologic response. Median overall survival (OS) was 4.5, 4.6, and 9.5 months for the BSC, FUFA, and mGEMOX arms (P = .039), respectively. Progression-free survival (PFS) was 2.8, 3.5, and 8.5 months for the three groups (P < .001). There was no difference in grade 3/4 toxicities in the chemotherapy arms except transaminitis, which was more prevalent in mGEMOX arm (P = .04). Two patients in the FUFA arm and 10 patients in the mGEMOX arm had grade 3 or 4 myelosuppression. Two patients in the mGEMOX group had neutropenic fever that resolved with antibiotics. Conclusion: This randomized controlled trial confirmed the efficacy of chemotherapy (mGEMOX) compared with BSC and FUFA in improving OS and PFS in unresectable GBC.

1 April 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
ASAtul Sharma
Atul Sharma
GRG.K. Rath
G.K. Rath
SCS.P. Chaudhary
S.P. Chaudhary
ATAlok Thakar
Alok Thakar
BMBidhu Kalyan Mohanti
Bidhu Kalyan Mohanti
SBSudhir Bahadur
Sudhir Bahadur

1 June 2013 in Head & Neck
Verified
Journal Article
Closed access
PDF file
ABAnkur Bahl
Ankur Bahl
PKPankaj Kumar
Pankaj Kumar
LDLalit Dar
Lalit Dar
BMBidhu K. Mohanti
Bidhu K. Mohanti
ASAtul Sharma
Atul Sharma
JLJaini Lodha
Jaini Lodha

28 April 2010 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ASA. Sharma
A. Sharma
BMB. K. Mohanti
B. K. Mohanti
ATA. Thakar
A. Thakar
SBS. Bahadur
S. Bahadur
SBS. Bhasker
S. Bhasker
Background: To know the effectiveness and tolerance of weekly cisplatin added to radiotherapy (RT) in advanced carcinoma of oropharynx and nasopharynx. Patients and methods: Stage II–IV cancer patients were randomly assigned to either radical RT, 70 Gy/35 fractions over 7 weeks (RT arm), or chemoradiotherapy (CRT), cisplatin 40 mg/m2 weekly for seven doses plus RT. Primary end points were (i) the responses, (ii) toxicity profile, and (iii) overall survival (OS) in two groups. Study period was from June 2003 to July 2005. Results: One hundred and fifty-three patients were randomly allocated to the study, 76 in RT arm and 77 in CRT arm. Seventy-one in each arm completed the planned treatment; complete response (CR): 67.1% versus 80.5% in RT and CRT arms (P = 0.04). Grade III and IV toxicity were 16% and 40% in RT and CRT arms, respectively (P = 0.01). There were frequent treatment interruptions (9.3% versus 28.9%; P = 0.003) and hospitalization (20% versus 40.8%) in the CRT group. OS was superior in the CRT arm (P = 0.02): 27 months [95% confidence interval (CI) 15.2–36.8] for RT versus not reached for CRT. Three-year OS was 42% for RT and 62% for CRT group. CRT and CR were independent prognostic factors. Conclusion: This trial on Indian head and neck squamous cell carcinoma patients confirms that the use of weekly cisplatin is safe and CRT is superior to RT alone resulting in higher OS.

1 December 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
ASAtul Sharma
Atul Sharma
BMBIDHU K MOHANTI
BIDHU K MOHANTI
SCSurendra Pal Chaudhary
Surendra Pal Chaudhary
VSV. Sreenivas
V. Sreenivas
RSRanjit Kumar Sahoo
Ranjit Kumar Sahoo
VRVinod Raina
Vinod Raina

20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASAkhil Santhosh
Akhil Santhosh
ASAtul Sharma
Atul Sharma
SBSameer Bakhshi
Sameer Bakhshi
AKAkash Kumar
Akash Kumar
VSVinod Sharma
Vinod Sharma
OIon behalf of the D-TORCH Trial Investigators
on behalf of the D-TORCH Trial Investigators
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events. Therefore, we conducted this study to assess the efficacy of topical diclofenac in the prevention of capecitabine-induced HFS. METHODS: In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned in a 1:1 ratio to receive topical diclofenac or placebo gel for 12 weeks or until the development of HFS, whichever occurred earlier. The primary end point was the incidence of grade 2 or 3 HFS (Common Terminology Criteria for Adverse Events version 5), which was compared between the two groups using simple logistic regression. RESULTS: In total, 264 patients were randomly assigned to receive topical diclofenac gel (n = 131) or placebo (n = 133). Grade 2 or 3 HFS was observed in 3.8% of participants in the diclofenac group compared with 15.0% in the placebo group (absolute difference, 11.2%; 95% CI, 4.3 to 18.1; P = .003). Grade 1-3 HFS was lower in the diclofenac group than in the placebo group (6.1% v 18.1%; absolute risk difference, 11.9%; 95% CI, 4.1 to 19.6). Capecitabine dose reductions because of HFS were less frequent in the diclofenac group (3.8%) than in the placebo group (13.5%; absolute risk difference, 9.7%; 95% CI, 3.0 to 16.4). CONCLUSION: Topical diclofenac prevented HFS in patients receiving capecitabine. This trial supports the use of topical diclofenac to prevent capecitabine-associated HFS.